This monoclonal antibody recognizes the HER2 receptor (human epidermal growth factor receptor 2), which is overexpressed in about 25–30% of breast tumours, and its clinical use has significantly changed the natural history of HER2-positive breast cancer (BC). This evidence concerns the gene ERBB2 and breast cancer.